Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price following the withdrawal of 2025 guidance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Centene between December 12, 2024, and June 30, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Company Performance and Stock Impact - Centene's stock price fell dramatically from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [5]. - The company announced a reduction in its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75, following a disappointing analysis of its market growth [4]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit-sub ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors about its financial health and growth prospects, leading to a significant drop in stock price [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - The allegations center around claims that Centene and its executives provided an overly optimistic view of the company's financial situation, particularly regarding revenue outlook and enrollment rates [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states, which accounts for 72% of its marketplace membership, was "lower than expected," leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by more than 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigative Actions - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its actual performance metrics [6].

Core Insights - Superior HealthPlan has been providing community hygiene closets since 2020 to support families in need across Texas [2][3] - The initiative has received over $700,000 in funding to assist communities, addressing the lack of personal care items not covered by SNAP [3][4] - Superior HealthPlan is a leading managed care organization serving 2 million people in Texas and has contributed $11.9 million in grants and sponsorships since 2020 [8] Program Details - The community hygiene closets are stocked with essential personal care products and are offered at no cost [1][4] - Currently, the initiative operates in 20 communities, with nearly 30 hygiene closets supported in 2025 [5][6] - The program was introduced during the early stages of the COVID-19 pandemic and expanded based on positive feedback from the community [4] Community Impact - The initiative is crucial for low-income families, as personal care items are not included in SNAP benefits, which serve approximately 3.5 million low-income Texans [3] - Local organizations, such as the NET Health Women, Infants and Children (WIC) department, express appreciation for the support provided by Superior HealthPlan [5] - Superior HealthPlan employs 3,500 individuals across Texas, emphasizing local involvement in all 254 counties [8]

NEW YORK, July 14, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025.So What: If you purchased Centene securities during the Class Peri ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...

Core Insights - Centene Corp. has experienced a significant decline of over 40% recently, indicating potential structural issues beyond mere market reactions [1] - The Adhishthana framework suggests that Centene's stock has broken down from a critical formation, leading to a bearish outlook [4][5] Technical Analysis - The stock typically forms a structure called the Adhishthana Cakra, which ideally should break out positively in Phase 9; however, Centene's breakdown is a bearish signal [2][4] - Currently, Centene is in Phase 7 on the monthly chart, with projections indicating it will not complete Phase 13 until November 30, 2032, suggesting a prolonged period of weakness [5] - The weekly chart reflects similar concerns, with Centene in Phase 14, indicating a challenging path ahead before reaching its cycle peak in Phase 18 [6][7] Investor Outlook - The recent decline is characterized as the Move of Pralayā, indicating serious underlying issues rather than a normal correction [8] - Centene is facing allegations of violating federal securities laws, which aligns with the timing of its stock's decline, reinforcing the bearish interpretation [9] - Minor rallies in this environment are expected to be unsustainable, with the monthly chart indicating continued downside pressure [10] Recommendations - Current investors should carefully assess their risk exposure, while new investors are advised against chasing dips due to the likelihood of short-lived upside [13]

Health insurer Elevance Health Inc. ELV is scheduled to release its second quarter 2025 financial results on July 17.Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, as per data from Benzinga Pro.UnitedHealth Group Inc. UNH has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial results on July 29.As it’s the biggest player in the industry, Forbes wr ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to a significant drop in its stock price, with allegations of misleading investors about the company's financial health and growth prospects during a specified class period [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1][2]. - Accusations include that Centene and its executives presented an overly optimistic view of the company's financial status, claiming reliable information about projected revenue and growth while actual metrics indicated lower enrollment and increased morbidity [3][4]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states, which account for 72% of its marketplace membership, was lower than expected, leading to a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price fell by over 40%, resulting in billions of dollars in lost shareholder value [5]. Group 3: Investigation and Response - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][6]. - The firm suggests that if the allegations are proven true, they indicate a disconnect between Centene's public statements and its internal performance metrics, potentially leaving investors at a loss [6].